In fact, in individuals carrying BRCA1/BRCA2 germ‐line mutations predisposing to breast and ovarian cancer, screening and prevention protocols have demonstrated their efficacy in terms of gain of life expectancy 38. This evidence concerns the gene BRCA2 and ovarian carcinoma.